Company insight The silent kidneys
The International Diabetes Federation projects a global diabetes incidence of 643 million by 2030. Diabetic kidney disease (DKD) occurs in up to 40% of patients with diabetes. Although albumin-creatinine ratio (ACR) is known to be the earliest marker of kidney disease, frequency of ACR testing remains low. Pharmaceutical company Abbott explores how quantitative ACR point-of- care testing improves DKD diagnosis and is a game-changer for better overall patient management.
B
etween 8–16% of the adult population have some form of kidney damage, and every year millions die prematurely of complications related to chronic kidney disease (CKD). Over time, worsening diabetic kidney disease (DKD) is associated with increased risk of cardiovascular events, cerebrovascular events and renal morbidity and mortality. In developed countries, end-stage renal disease (ESRD) is a major cost driver for patients, their families and the taxpayer. Patients with ESRD require dialysis or kidney transplantation, which are highly costly and consume a sizeable portion of the health budget.
In people with diabetes, cardiovascular and renal complications are the main cause of death, yet the majority of these patients are unaware of having diabetes complications. Kidney disease is often described as ‘silent’ because 90% of function can be lost before symptoms are experienced. Recent studies have found that one in ten adults could be affected, yet only one third of these will have had a diagnosis.
ACR measurement can be achieved with laboratory testing and point-of-care testing. Point-of-care testing in primary care allows patients and their care providers to make management decisions.
is key to initiating treatment and to halting progression of the disease.
ACR is the earliest marker ACR levels are associated with risk of cardiovascular disease, kidney disease progression and mortality. KDIGO recommends a comprehensive staging for CKD that incorporates albuminuria at all stages of estimated glomerular
“The Abbott educational platform myPOCacademy is an expert resource for healthcare professionals, providing a range of professionally accredited learning on POCT.”
The same study showed that mortality was substantial in this population, and that the leading cause of hospital visits and costs was CKD followed by heart failure. This is despite the fact that early detection and management of kidney disease can slow disease progression or even prevent it altogether. Early detection of cardiovascular and renal complications
16
filtration rate (eGFR). In patients with type 2 diabetes, diagnosis of DKD helps clinicians to adjust hypoglycaemic medication, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium- glucose cotransporter-2 (SGL-2) inhibitors, by avoiding contraindicated drugs and using others with caution to avoid serious complications, such as hypoglycemias.
ACR is also known to be the earliest marker of kidney disease. A recent study found that routine measurement of ACR at the point-of-care in diabetes patients identified 8.6% with DKD and 9.9% with suspected DKD. In the group of patients with DKD, the medication was then adjusted in 46% of patients based on the ACR values.
ACR can prove a useful screening tool for CKD and microvascular complications as well. Despite all this, frequency of ACR measurement is still low in many countries.
Rapid point-of-care testing ACR measurement can be achieved with both laboratory testing and point-of-care testing (POCT). POCT in primary care allows patients and their care providers to make management decisions at the time of the visit of a patient. Results are available within minutes and can be discussed with the patient immediately. POCT has the potential to improve practice workflow, leading to operational and economic benefits. For patients, this is more convenient and has been shown to increase understanding, motivation and
Practical Patient Care /
www.practical-patient-care.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
